Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

State-of-the-art-review Mechanisms of action of SGLT2 inhibitors and clinical implications
Volker Vallon
American Journal of Hypertension (2024) Vol. 37, Iss. 11, pp. 841-852
Closed Access | Times Cited: 12

Showing 12 citing articles:

Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice
Helen Goodluck, Alice Zemljic‐Harpf, Ony Araújo Galdino, et al.
Physiological Reports (2025) Vol. 13, Iss. 7
Open Access | Times Cited: 1
Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Joyce Yip, Grace Shu Hui Chiang, I Lee, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 364-364
Open Access
A study on the pharmacovigilance of various SGLT-2 inhibitors
Yanwen Dong, Yangyang Wang, Xiao-mei Lan, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access
Chronic Heart Failure and Coronary Artery Disease: Pharmacological Treatment and Cardiac Rehabilitation
Maria-Alexandra Pană, Aristi Boulmpou, Çiğdem İleri, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 211-211
Open Access
Research recommendations from the 2024 Breakthrough T1D, Diabetes UK and Kidney Research UK, diabetes and kidney disease expert workshop
Zoe Markham‐Lee, Swati Bhagat‐Jones, Jill Carlton, et al.
Diabetic Medicine (2025)
Open Access
Sodium-glucose co-transporters (SGLT2) inhibitors prevent lipid droplets formation in vascular inflammation or lipid overload by SGLT2-independent mechanism
Natalia Chorazy, Kamila Wojnar‐Lason, Anna M. Gdula, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 185, pp. 117967-117967
Closed Access
The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage
Martina Hüttl, Matúš Miklovič, Olga Gawryś, et al.
Journal of Hypertension (2025)
Closed Access
SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes
Yun Wen, Xiaofang Zhang, Han Liu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Water and sodium conservation response induced by SGLT2 inhibitor ipragliflozin in Dahl salt-sensitive hypertensive rats
Takahiro Masuda, Masahide Yoshida, Tatsushi Onaka, et al.
Hypertension Research (2024)
Closed Access | Times Cited: 1
Glomerular pressure and tubular oxygen supply: a critical dual target for renal protection
Takahiro Masuda, Daisuke Nagata
Hypertension Research (2024)
Closed Access | Times Cited: 1
SGLT 2 Inhibitors: Mechanisms, Clinical Applications, and Future Directions
Alpay Çakmak
International Journal of Computational and Experimental Science and Engineering (2024) Vol. 10, Iss. 4
Open Access | Times Cited: 1
SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives
Cassandra Morciano, Shawn Gugliandolo, Umberto Capece, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Page 1

Scroll to top